- Home
- INCR vs AADI Comparison
INCR vs AADI Comparison
Compare INCR & AADI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- AADI
- Stock Information
- Founded
- INCR 1994
- AADI 2011
- Country
- INCR Israel
- AADI United States
- Employees
- INCR N/A
- AADI N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- AADI Biotechnology: Pharmaceutical Preparations
- Sector
- INCR Health Care
- AADI Health Care
- Exchange
- INCR Nasdaq
- AADI Nasdaq
- Market Cap
- INCR 65.3M
- AADI 59.4M
- IPO Year
- INCR N/A
- AADI N/A
- Fundamental
- Price
- INCR $1.46
- AADI $2.36
- Analyst Decision
- INCR
- AADI Hold
- Analyst Count
- INCR 0
- AADI 3
- Target Price
- INCR N/A
- AADI $1.75
- AVG Volume (30 Days)
- INCR 29.6K
- AADI 109.6K
- Earning Date
- INCR 12-24-2024
- AADI 11-06-2024
- Dividend Yield
- INCR N/A
- AADI N/A
- EPS Growth
- INCR N/A
- AADI N/A
- EPS
- INCR N/A
- AADI N/A
- Revenue
- INCR $72,420,918.00
- AADI $25,070,000.00
- Revenue This Year
- INCR N/A
- AADI $9.39
- Revenue Next Year
- INCR $39.30
- AADI $6.15
- P/E Ratio
- INCR N/A
- AADI N/A
- Revenue Growth
- INCR N/A
- AADI 7.80
- 52 Week Low
- INCR $1.17
- AADI $1.21
- 52 Week High
- INCR $3.72
- AADI $2.63
- Technical
- Relative Strength Index (RSI)
- INCR 52.10
- AADI 58.75
- Support Level
- INCR $1.30
- AADI $2.25
- Resistance Level
- INCR $1.47
- AADI $2.45
- Average True Range (ATR)
- INCR 0.05
- AADI 0.11
- MACD
- INCR 0.02
- AADI -0.01
- Stochastic Oscillator
- INCR 88.83
- AADI 39.89
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
About AADI Aadi Bioscience Inc.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.